Large gap with delayed quotes
Analysis date: 28.10.2025
                Global Evaluation
                
Slightly negative
        Slightly negative
The stock is classified in the slightly negative zone since 28.10.2025.
    
                Interest
                
Weak
        Weak
Two stars since 28.10.2025.
    
                Earnings Rev Trend
                
Positive
        Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 26.09.2025 at a price of 77.00.
    
                Evaluation
                
Undervalued
        Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
    
                MT Tech Trend
                
Negative
        Negative
The dividend-adjusted forty day technical trend is negative since 24.10.2025.
    
                4wk Rel Perf
                
-1.49%
        -1.49%
The four-week dividend-adjusted underperformance versus STOXX600 is 1.49%. 
    
                Sensibility
                
High
        High
The stock has been on the high-sensitivity level since 27.05.2025.
    
                Bear Market Factor
                
Middle
        Middle
On average, the stock is likely to decline with the index.
    
                Bad News Factor
                
Low
        Low
When the stock's pressure is specific, the market sanction on average is 3.96%.
    
                Mkt Cap in $bn
                
1.89
        1.89
With a market capitalization <$2bn, REDCARE PHARMACY is considered a small-cap stock.
    
                G/PE Ratio
                
6.11
        6.11
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
    
                LT P/E
                
22.08
        22.08
The estimated PE is for the year 2027.
    
                LT Growth
                
134.92%
        134.92%
The annualized growth estimate is for the current year to 2027.
    
                Avg. Nb analysts
                
10
        10
Over the last seven weeks, an average of 10 analysts provided earnings per share estimates.
    
                Dividend Yield
                
0.00%
        0.00%
The company is not paying a dividend.
    
                Beta
                
46
        46
For 1% of index variation, the stock varies on average by 0.46%.
    
                Correlation
                
0.14
        0.14
Stock movements are totally independent of index variations.
    
                Value at Risk
                
25.08
        25.08
The value at risk is estimated at EUR 25.08. The risk is therefore 31.82%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
    
                First Analysis Date
                
03.11.2017
        03.11.2017